RBC Capital Keeps Their Buy Rating on Keurig Dr Pepper (KDP)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Modi covers the Consumer Defensive sector, focusing on stocks such as Constellation Brands, Procter & Gamble, and Clorox. According to TipRanks, Modi has an average return of 1.2% and a 51.98% success rate on recommended stocks.
In addition to RBC Capital, Keurig Dr Pepper also received a Buy from Wells Fargo's Christopher Carey in a report issued yesterday. However, on July 2, Evercore ISI maintained a Hold rating on Keurig Dr Pepper (NASDAQ: KDP).
Based on Keurig Dr Pepper's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.64 billion and a net profit of $517 million. In comparison, last year the company earned a revenue of $3.47 billion and had a net profit of $454 million
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is neutral on the stock. Last month, Michael Van-Ven, a Director at KDP bought 15,000.00 shares for a total of $498,000.00.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update. To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10200686, or click on this and request a return call with passcode 0605709. The audio webcast can be accessed live on this and also on the 'Investor Relations' page of the Spero Corporate Website at The archived webcast will also be available on Spero's website for 30 days following the call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need. For more information, visit Spero Investor Relations Contact:Shai Biran, PhDSpero Therapeutics IR@ Spero Media Inquiries: media@ in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
MongoDB, Inc. Announces Date of Second Quarter Fiscal 2026 Earnings Call
NEW YORK, Aug. 5, 2025 /PRNewswire/ -- MongoDB, Inc. (NASDAQ: MDB) today announced it will report its second quarter fiscal year 2026 financial results for the three months ended July 31, 2025, after the U.S. financial markets close on Tuesday, August 26, 2025. In conjunction with this announcement, MongoDB will host a conference call on Tuesday, August 26, 2025, at 5:00 p.m. (Eastern Time) to discuss the Company's financial results and business outlook. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at About MongoDB Headquartered in New York, MongoDB's mission is to empower innovators to create, transform, and disrupt industries with software and data. MongoDB's unified, intelligent data platform was built to power the next generation of applications, and MongoDB is the most widely available, globally distributed database on the market. With integrated capabilities for operational data, search, real-time analytics, and AI-powered retrieval, MongoDB helps organizations everywhere move faster, innovate more efficiently, and simplify complex architectures. Millions of developers and more than 50,000 customers across almost every industry—including 70% of the Fortune 100—rely on MongoDB for their most important applications. To learn more, visit Investor RelationsBrian DenyeauICR for MongoDB646-277-1251ir@ Media RelationsMongoDBpress@ View original content to download multimedia: SOURCE MongoDB, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
LifeMD Reports Second Quarter 2025 Results
Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 million Telehealth revenue increased 30% to $48.6 million; telehealth adjusted EBITDA rose 560% to $3.4 million Generated more than $8 million of operating cash flow Paid down $2.1 million of senior debt, exited the quarter with $36.2 million in cash and fully repaid all remaining senior debt subsequent to quarter-end Enhanced and diversified virtual care platform with nationwide launch of behavioral health offering, upgraded LifeMD+ membership program and acquisition of women's health practice NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three and six months ended June 30, 2025. Management Commentary 'The second quarter of 2025 was an extremely productive quarter for LifeMD and the evolution of our telehealth platform,' said Justin Schreiber, Chairman and CEO of LifeMD. 'Hundreds of thousands of patients now trust LifeMD to deliver affordable, accessible virtual care that meaningfully improves their health outcomes. Our platform is undergoing a transformational expansion, broadening our clinical scope into some of the most pressing and underserved areas of healthcare at a time when innovation is desperately needed. Technology-enabled virtual and in-home care platforms like ours are critical to closing this gap, and I believe we are exceptionally well positioned to transform the lives of millions of Americans in the years ahead. 'A key highlight of the second quarter was the diversification of our platform into high-need clinical areas. We launched a nationwide behavioral health offering that's unique in its ability to support both synchronous and asynchronous care, and we acquired a virtual women's health brand to accelerate our entry into this segment. In addition, we began scaling our enhanced LifeMD+ membership program, which highlights 24/7 urgent and primary care, and aggregates specialty care, prescription medications, in-home labs and wellness products and services that can help our customers manage their overall health,' Schreiber continued. 'Our long-term financial outlook remains strong and we continue to make significant strides in diversifying our offerings to optimize our position for growth and profitability,' said Marc Benathen, LifeMD's Chief Financial Officer. 'We exited the quarter with $36.2 million in cash and have now fully paid off all senior debt, significantly strengthening our balance sheet. Telehealth revenue grew 30% year-over-year and telehealth adjusted EBITDA increased 560%. WorkSimpli continued to perform well, with adjusted EBITDA increasing 119% versus the prior-year quarter. Due to some temporary challenges facing our Rex MD business—which are now largely resolved—we are revising our full-year 2025 guidance for revenue and adjusted EBITDA to reflect the full-year impact of these issues, while still anticipating strong year-over-year growth in both metrics.' Second Quarter Financial Highlights All comparisons are with the second quarter of 2024. Non-GAAP financial measures referenced below are defined and reconciled to GAAP financial measures at the end of this press release. Total revenue increased 23% to $62.2 million, driven by a 30% increase in telehealth revenue. The number of active telehealth subscribers increased 16% to approximately 297,000 at quarter-end. Gross margin was 88% compared to 90% in the prior-year period due to revenue mix. GAAP net loss was $2.9 million or ($0.06) per share compared to a net loss of $7.7 million or ($0.19) per share in the prior-year period. Adjusted EBITDA was $7.1 million compared to $2.2 million in the prior-year period. Telehealth adjusted EBITDA was $3.4 million compared to $0.5 million in the prior-year period. Cash totaled $36.2 million as of June 30, 2025 inclusive of paying down $2.1 million of senior debt during the quarter, an increase of $1.8 million from March 31, 2025. Subsequent to quarter-end, all remaining senior debt was fully repaid from existing cash. Second Quarter Key Performance Metrics ($ in 000s) Three Months Ended June 30, Y-o-Y Key Performance Metrics 2025 2024 % Growth Revenue Telehealth $ 48,564 $ 37,432 30 % WorkSimpli $ 13,655 $ 13,230 3 % Total Revenue $ 62,218 $ 50,662 23 % Active Subscribers Telehealth Active Subscribers 296,946 256,387 16 % WorkSimpli Active Subscribers 149,465 158,265 -6 % Total Active Subscribers 446,411 414,652 8 % Financial Guidance For the third quarter of 2025, the Company expects: Total revenue in the range of $61 million to $63 million, with telehealth revenue in the range of $48 million to $50 million. Adjusted EBITDA in the range of $6 million to $7 million, with telehealth adjusted EBITDA in the range of $3 million to $4 million. For the full year 2025, the Company expects: Total revenue in the range of $250 million to $255 million, compared with previous guidance of $268 million to $275 million. Telehealth revenue in the range of $195 million to $200 million, compared with $208 million to $213 million previously. Adjusted EBITDA in the range of $27 million to $29 million, compared with $31 million to $33 million previously. Telehealth adjusted EBITDA is now forecast to be in the range of $14 million to $16 million, down from $21 million previously. Conference Call LifeMD's management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company's financial results and outlook, and answer questions. Details for the call are as follows: Toll-free dial-in number: 800-445-7795 International dial-in number: 785-424-1699 Conference ID: LIFEMD A live and archived webcast will be available in the Investors section of the Company's website at About LifeMD LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit Cautionary Note Regarding Forward Looking Statements This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: 'believe,' 'expect,' 'anticipate,' 'project,' 'should,' 'plan,' 'will,' 'may,' 'intend,' 'estimate,' predict,' 'continue,' and 'potential,' or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition. Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, 'Risk Factors' identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods. Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation. Investor ContactMarc Benathen, Chief Financial Officermarc@ Media ContactJessica Friedeman, Chief Marketing and Product Officerpress@ Tables to Follow LIFEMD, INC. CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 (Unaudited) ASSETS Current Assets Cash $ 36,228,305 $ 35,004,924 Accounts receivable, net 7,330,129 8,217,813 Product deposit 251,000 40,763 Inventory, net 3,251,355 2,797,358 Other current assets 1,964,974 2,672,231 Total Current Assets 49,025,763 48,733,089 Non-current Assets Equipment, net 2,050,318 1,479,184 Right of use assets 5,822,907 6,400,596 Capitalized software, net 14,837,946 13,816,501 Intangible assets, net 1,827,768 2,030,656 Total Non-current Assets 24,538,939 23,726,937 Total Assets $ 73,564,702 $ 72,460,026 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable $ 24,292,870 $ 16,009,484 Accrued expenses 14,946,499 20,811,764 Current operating lease liabilities 541,981 508,537 Current portion of long-term debt 11,960,784 8,444,444 Deferred revenue 11,790,024 14,480,917 Total Current Liabilities 63,532,158 60,255,146 Long-term Liabilities Long-term debt, net 3,517,317 9,885,057 Noncurrent operating lease liabilities 6,032,847 6,265,192 Contingent consideration 100,000 100,000 Total Liabilities 73,182,322 76,505,395 Commitments and Contingencies Mezzanine Equity Preferred Stock, $0.0001 par value; 5,000,000 shares authorized Series B Convertible Preferred Stock, $0.0001 par value; 5,000 shares authorized, zero shares issued and outstanding, liquidation value, $0 per share as of June 30, 2025 and December 31, 2024 - - Stockholders' Equity (Deficit) Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately $25.55 per share as of June 30, 2025 and December 31, 2024 140 140 Common Stock, $0.01 par value; 100,000,000 shares authorized, 45,141,226 and 42,293,907 shares issued, 45,038,186 and 42,190,867 outstanding as of June 30, 2025 and December 31, 2024, respectively 451,412 422,939 Additional paid-in capital 236,426,008 230,508,339 Accumulated deficit (238,496,413 ) (236,253,218 ) Treasury stock, 103,040 shares, at cost, as of June 30, 2025 and December 31, 2024 (163,701 ) (163,701 ) Total LifeMD, Inc. Stockholders' Deficit (1,782,554 ) (5,485,501 ) Non-controlling interest 2,164,934 1,440,132 Total Stockholders' Equity (Deficit) 382,380 (4,045,369 ) Total Liabilities, Mezzanine Equity and Stockholders' Equity (Deficit) $ 73,564,702 $ 72,460,026 LIFEMD, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues Telehealth revenue, net $ 48,563,672 $ 37,432,309 $ 101,020,153 $ 68,273,711 WorkSimpli revenue, net 13,654,513 13,229,536 26,895,788 26,532,398 Total revenues, net 62,218,185 50,661,845 127,915,941 94,806,109 Cost of revenues Cost of telehealth revenue 6,838,703 4,553,843 14,975,164 8,748,438 Cost of WorkSimpli revenue 592,201 471,072 1,099,456 876,654 Total cost of revenues 7,430,904 5,024,915 16,074,620 9,625,092 Gross profit 54,787,281 45,636,930 111,841,321 85,181,017 Expenses Selling and marketing expenses 29,125,097 26,378,928 58,319,158 50,552,808 General and administrative expenses 17,565,187 18,521,385 34,620,856 33,827,117 Customer service expenses 3,230,735 2,733,418 6,302,229 4,581,459 Other operating expenses 3,028,762 1,906,175 5,543,520 4,206,622 Development costs 2,744,272 2,402,590 5,419,406 4,489,822 Total expenses 55,694,053 51,942,496 110,205,169 97,657,828 Operating (loss) income (906,772 ) (6,305,566 ) 1,636,152 (12,476,811 ) Other expenses Interest expense, net (663,027 ) (531,468 ) (1,289,302 ) (1,009,146 ) Net (loss) income before income taxes (1,569,799 ) (6,837,034 ) 346,850 (13,485,957 ) Income tax expense - - - - Net (loss) income (1,569,799 ) (6,837,034 ) 346,850 (13,485,957 ) Net income attributable to noncontrolling interests 505,075 38,606 1,036,920 158,038 Net loss attributable to LifeMD, Inc. (2,074,874 ) (6,875,640 ) (690,070 ) (13,643,995 ) Preferred stock dividends (776,562 ) (776,562 ) (1,553,125 ) (1,553,125 ) Net loss attributable to LifeMD, Inc. common stockholders $ (2,851,436 ) $ (7,652,202 ) $ (2,243,195 ) $ (15,197,120 ) Basic loss per share attributable to LifeMD, Inc. common stockholders $ (0.06 ) $ (0.19 ) $ (0.05 ) $ (0.38 ) Diluted loss per share attributable to LifeMD, Inc. common stockholders $ (0.06 ) $ (0.19 ) $ (0.05 ) $ (0.38 ) Weighted average number of common shares outstanding: Basic 44,401,531 41,296,042 43,772,151 40,269,139 Diluted 44,401,531 41,296,042 43,772,151 40,269,139 LIFEMD, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net (loss) income $ (1,569,799 ) $ (6,837,034 ) $ 346,850 $ (13,485,957 ) Adjustments to reconcile net (loss) income to net cash provided by operating activities: Amortization of debt discount 100,444 100,444 200,888 200,888 Amortization of capitalized software 2,377,484 1,937,708 4,627,520 3,725,112 Amortization of intangibles 261,360 246,066 505,888 492,032 Accretion of consideration payable - - - 13,644 Depreciation of fixed assets 184,256 104,451 346,822 170,366 Noncash operating lease expense 281,956 184,588 577,689 391,397 Stock compensation expense 2,094,614 4,191,176 4,643,142 6,735,606 Changes in Assets and Liabilities Accounts receivable 2,862,645 (331,451 ) 887,684 (390,692 ) Product deposit (59,160 ) 172,804 (210,237 ) 369,716 Inventory (283,658 ) 312,921 (453,997 ) 699,213 Other current assets 262,226 (222,683 ) 707,257 (586,910 ) Operating lease liabilities (94,004 ) (130,846 ) (198,901 ) (334,790 ) Deferred revenue (2,835,878 ) 1,958,902 (2,690,893 ) 6,333,061 Accounts payable 8,613,842 2,656,697 8,283,386 3,966,874 Accrued expenses (3,556,881 ) 196,020 (5,865,264 ) 1,442,362 Net cash provided by operating activities 8,639,447 4,539,763 11,707,834 9,741,922 CASH FLOWS FROM INVESTING ACTIVITIES Cash paid for capitalized software costs (2,903,838 ) (2,488,039 ) (5,648,965 ) (4,502,712 ) Purchase of equipment (795,745 ) (642,053 ) (917,956 ) (817,645 ) Purchase of intangible assets - (1,936 ) - (1,936 ) Net cash used in investing activities (3,699,583 ) (3,132,028 ) (6,566,921 ) (5,322,293 ) CASH FLOWS FROM FINANCING ACTIVITIES Repayment of notes payable, net of prepayment penalty - (102,887 ) - (314,577 ) Repayment of debt instruments (2,052,288 ) - (2,052,288 ) - Cash proceeds from exercise of options - 100,000 - 107,813 Preferred stock dividends (776,562 ) (776,562 ) (1,553,125 ) (1,553,125 ) Contingent consideration payment for ResumeBuild - - - (31,250 ) Distributions to non-controlling interest (276,119 ) (36,000 ) (312,119 ) (72,000 ) Net cah used in financing activities (3,104,969 ) (815,449 ) (3,917,532 ) (1,863,139 ) Net increase in cash 1,834,895 592,286 1,223,381 2,556,490 Cash at beginning of period 34,393,410 35,110,929 35,004,924 33,146,725 Cash at end of period $ 36,228,305 $ 35,703,215 $ 36,228,305 $ 35,703,215 Cash paid for interest Cash paid during the period for interest $ 625,818 $ 637,788 $ 1,219,568 $ 1,282,707 Non-cash investing and financing activities: Cashless exercise of options $ 501 $ 4,489 $ 1,062 $ 5,127 Cashless exercise of warrants $ 3,901 $ 3,620 $ 3,901 $ 16,305 Stock issued for debt conversion $ 1,000,000 $ - $ 1,000,000 $ - Stock issued for asset acquisition $ 303,000 $ - $ 303,000 $ - Stock issued for noncontingent consideration payments $ - $ - $ - $ 642,000 Right of use asset $ - $ 1,045,305 $ - $ 2,331,231 Operating lease liabilities $ - $ 1,045,305 $ - $ 2,331,231 About the Use of Non-GAAP Financial Measures:To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. Additionally, we report telehealth adjusted EBITDA as a non-GAAP financial measure to clarify the financial performance of our core telehealth business excluding WorkSimpli. We believe that the presentation of these financial measures enhances an investor's understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. Adjusted EBITDA is defined as income (loss) attributable to common shareholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests, foreign currency translation, extraordinary litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness expenses, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to common shareholders, its most directly comparable GAAP financial measure. Telehealth and WorkSimpli adjusted EBITDA is defined as segment operating income or loss before depreciation, amortization, accretion, financing transaction expense, extraordinary litigation costs, insurance acceptance and Sarbanes-Oxley readiness expenses, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of segment operating income or loss to segment Adjusted EBITDA. We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted EBITDA may vary from that of others in our industry. Telehealth adjusted EBITDA is specifically relevant to LifeMD to provide shareholders a comparable measure of profitability for our core telehealth business without the impact of our majority owned, but separately managed non-core subsidiary, WorkSimpli. Adjusted EBITDA, telehealth adjusted EBITDA and WorkSimpli adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance. Reconciliation of Consolidated GAAP Net Loss to Consolidated Adjusted EBITDA (in whole numbers, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net loss attributable to common shareholders $ (2,851,436 ) $ (7,652,202 ) $ (2,243,195 ) $ (15,197,120 ) Interest expense (excluding amortization of debt discount) 562,583 431,024 1,088,414 808,258 Depreciation, amortization and accretion expense 2,823,100 2,288,225 5,480,230 4,401,154 Amortization of debt discount 100,444 100,444 200,888 200,888 Financing transactions expense - 151,143 - 323,372 Litigation costs (a) 486,462 495,784 739,659 678,331 Severance costs 25,535 360,182 102,417 520,677 Acquisitions expenses 1,806,277 - 2,014,777 - Insurance acceptance readiness 34,780 263,492 175,140 969,834 Sarbanes Oxley readiness - 23,220 - 183,128 Foreign exchange loss 253,512 504,969 485,159 478,721 Taxes 502,408 3,000 502,408 3,000 Dividends 776,562 1,004,793 1,553,125 2,048,173 Stock-based compensation expense 2,094,614 4,191,176 4,643,142 6,735,606 Net income attributable to noncontrolling interests 505,075 38,606 1,036,920 158,038 Consolidated Adjusted EBITDA $ 7,119,915 $ 2,203,856 $ 15,779,084 $ 2,312,060 Reconciliation of Telehealth GAAP Operating Loss to Telehealth Adjusted EBITDA (in whole numbers, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Telehealth operating loss $ (2,802,097 ) $ (6,450,683 ) $ (2,415,231 ) $ (13,070,446 ) Depreciation, amortization and accretion expense 1,785,344 1,485,696 3,476,753 2,848,770 Financing transactions expense - 151,143 - 323,372 Litigation costs (a) 486,462 495,784 739,659 678,331 Severance costs 25,535 360,182 102,417 520,677 Acquisitions expenses 1,806,277 - 2,014,777 - Insurance acceptance readiness 34,780 263,492 175,140 969,834 Sarbanes Oxley readiness - 23,220 - 183,128 Stock-based compensation expense 2,094,614 4,191,176 4,643,142 6,735,606 Telehealth Adjusted EBITDA $ 3,430,914 $ 520,010 $ 8,736,657 $ (810,728 ) (a) For the three and six months ended June 30, 2025 and June 30, 2024, the Company included costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case), as disclosed in the Company's Form 10-Q for the three and six months ended June 30, 2025, filed on August 5, 2025, and a heavily negotiated executive separation agreement. Reconciliation of WorkSimpli GAAP Operating Income to WorkSimpli Adjusted EBITDA (in whole numbers, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 WorkSimpli operating income $ 1,895,325 $ 145,116 $ 4,051,383 $ 593,635 Depreciation, amortization and accretion expense 1,037,756 802,529 2,003,477 1,552,384 Foreign exchange loss 253,512 504,969 485,159 478,721 Distributions - 228,231 - 495,048 Taxes 502,408 3,000 502,408 3,000 WorkSimpli Adjusted EBITDA $ 3,689,001 $ 1,683,845 $ 7,042,427 $ 3,122,788
